CAPITALIZING LEADERSHIP ACUMEN FOR LIFE SCIENCE INNOVATIONS
Allele partners with executive leaders demonstrating exceptional results (ELDERs™) in the life sciences industry to provide strategic advisory, proprietary capital and non-proprietary capital.Read More
“In 2008 during our company’s inception, we began working with Shawn to advise us on various aspects of our corporate planning and to assist us in raising capital. Over the years, Shawn has supported us in our company’s growth initiatives through investment, advice and capital markets support. We view Shawn as a value-added advisor and investor”.
Robert Finizio, Co-Founder and Chief Executive Officer TherapeuticsMD, Inc. (Nasdaq: TXMD)
"We first met and began working with Shawn in the Fall of 2016, during the structuring of a public merger in which he led the scientific diligence and market analysis. We were immediately impressed by his knowledge of the field of regenerative medicine as a whole, and his ability to instantly grasp the core concepts of our technology. Upon completion of the merger, Shawn was instrumental to our capital markets initiatives, serving as a strategic advisor to the Company. Shawn and Allele Capital Partners exemplify value-add investors, who are agile in their approach when unique opportunities present themselves."
Ned Swanson, MD, Executive Vice President, COO & Director PolarityTE, Inc. (Nasdaq: COOL)
"Menachem shared our vision and believed in our team pre Proof of Concept. He identified our risk mitigated scientific strategy of developing proprietary versions of already approved therapeutic proteins, extending their lifespan without additional toxicity or loss of desired biological activity. He invested his own capital and used his network to become a champion of our company."
Shai Novik, Former Chief Executive Officer Prolor Biotech, Inc. - Acquired by OPKO Health, Inc. (Nasdaq: OPK) in 2013
Allele’s Principals comprehensive experience in private-to-public and public venture process for micro and small-cap life sciences companies has resulted in significant shareholder equity and valuations of over $1 billion.